I was wrong." M Michael T
Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "GLP-1 Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target indication and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering
First up is being vigilant about the switch from compounded to FDA-approved GLP-1s
International Journal of Antimicrobial Agents , 25 , 404408
Go EJ, et al
Moreover, the success of incretin-based therapies has recalibrated tolerance for certain classes of adverse effects when balanced against substantial clinical benefit